Teva Pharmaceutical Industries in the context of "Bioequivalence"

Play Trivia Questions online!

or

Skip to study material about Teva Pharmaceutical Industries in the context of "Bioequivalence"





👉 Teva Pharmaceutical Industries in the context of Bioequivalence

Bioequivalence is a term in pharmacokinetics used to assess the expected in vivo biological equivalence of two proprietary preparations of a drug. If two products are said to be bioequivalent it means that they would be expected to be, for all intents and purposes, the same.

One article defined bioequivalence by stating that, "two pharmaceutical products are bioequivalent if they are pharmaceutically equivalent and their bioavailabilities (rate and extent of availability) after administration in the same molar dose are similar to such a degree that their effects, with respect to both efficacy and safety, can be expected to be essentially the same. Pharmaceutical equivalence implies the same amount of the same active substance(s), in the same dosage form, for the same route of administration and meeting the same or comparable standards."

↓ Explore More Topics
In this Dossier

Teva Pharmaceutical Industries in the context of Har Hotzvim

Har Hotzvim (Hebrew: הר חוצבים, lit. Stonecutter's Mountain), also Campus of Science-Rich Industries (קריית תעשיות עתירות מדע‎, Kiryat Ta'asiyot Atirot Mada) is a high-tech industrial park located in northwest Jerusalem. It is the city's main zone for science-based and technology companies, among them Intel, Teva, NDS (now Cisco), RAD Data, Mobileye, Ophir Optronics, Sandvine, Radware, IDT Global Israel, Medtronic, SATEC, Johnson and Johnson and more. In addition to large companies, the park also hosts about 100 small and medium-sized high-tech companies, as well as a technological incubator. In 2011, Har Hotzvim provided employment for 10,000 people.

↑ Return to Menu